1. Aberrant Regulation of mRNA m6A Modification in Cancer Development
    Junyun Luo et al, 2018, IJMS CrossRef
  2. Functions of RNA N6-methyladenosine modification in cancer progression
    Bing Chen et al, 2019, Mol Biol Rep CrossRef
  3. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions.
    Maximilian Brunner et al, 2019, Int J Mol Sci CrossRef
  4. microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance
    Wen Cai Zhang, 2019, IJMS CrossRef
  5. Multiple Functions and Mechanisms Underlying the Role of METTL3 in Human Cancers
    Wenhui Zheng et al, 2019, Front. Oncol. CrossRef
  6. N6-Methyladenosine: A Novel RNA Imprint in Human Cancer
    Sihui Yu et al, 2019, Front. Oncol. CrossRef
  7. VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer
    Daniela Barros-Silva et al, 2020, Cancers CrossRef
  8. Analysis of Genetic Alteration Signatures and Prognostic Values of m6A Regulatory Genes in Head and Neck Squamous Cell Carcinoma
    Xuanchen Zhou et al, 2020, Front. Oncol. CrossRef
  9. Molecular mechanism of methyltransferase-like protein family: Relationship with gastric cancer
    Jing Wang et al, 2020, WCJD CrossRef
  10. Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes
    Yu Takeda et al, 2020, Cells CrossRef
  11. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma
    Xiaomin Wu et al, 2020, BioMed Research International CrossRef
  12. Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine
    Na Li et al, 2020, EPMA Journal CrossRef
  13. m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma
    Fangwei Li et al, 2020, Front. Genet. CrossRef
  14. Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular Carcinoma
    Lele Zhang et al, 2020, Front. Med. CrossRef
  15. null
    María José López-Ibarra et al, 2020 CrossRef
  16. IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism.
    Jian Pu et al, 2020, Front Oncol CrossRef
  17. Characterization of Oral Microbiome and Exploration of Potential Biomarkers in Patients with Pancreatic Cancer
    Haiyang Sun et al, 2020, BioMed Research International CrossRef
  18. M6A Regulatory Genes Play an Important Role in the Prognosis, Progression and Immune Microenvironment of Pancreatic Adenocarcinoma.
    Fangshi Xu et al, 2021, Cancer Invest CrossRef
  19. Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer
    Peng-Ju Gong et al, 2020, Front. Oncol. CrossRef
  20. Head and Neck Squamous Cell Carcinoma: Epigenetic Landscape
    Kamila Romanowska et al, 2020, Diagnostics CrossRef
  21. Identification of Transcription Factors, Biological Pathways, and Diseases as Mediated by N6-methyladenosine Using Tensor Decomposition-Based Unsupervised Feature Extraction
    Y-h. Taguchi et al, 2020, Applied Sciences CrossRef
  22. Epigenetyka jako obiecująca dziedzina nauki w walce z nowotworami głowy i szyi
    Kamila Romanowska, 2021, LOS CrossRef
  23. Effects of Quercetin on the Efficacy of Various Chemotherapeutic Drugs in Cervical Cancer Cells
    Wenbin Xu et al, 2021, DDDT CrossRef
  24. Context-Dependent Roles of RNA Modifications in Stress Responses and Diseases
    Emma Wilkinson et al, 2021, IJMS CrossRef
  25. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma
    Chengquan Shen et al, 2021, Front. Endocrinol. CrossRef
  26. The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy
    Omprakash Shriwas et al, 2021, Front. Oncol. CrossRef
  27. N 6 ‐Methyladenosine (m 6 A) readers are dysregulated in renal cell carcinoma
    Felix Hagen et al, 2021, Molecular Carcinogenesis CrossRef
  28. NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response.
    Yong-Qiang Hua et al, 2021, Front Cell Dev Biol CrossRef
  29. Clinical and prognostic pan-cancer analysis of m6A RNA methylation regulators in four types of endocrine system tumors
    Kai Li et al, 2020, Aging CrossRef
  30. N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies
    Fenghua Tan et al, 2021, J Exp Clin Cancer Res CrossRef
  31. Role of RNA N6-Methyladenosine Modification in Male Infertility and Genital System Tumors
    Shuai Liu et al, 2021, Front. Cell Dev. Biol. CrossRef
  32. m6A RNA Methylation Regulators Elicit Malignant Progression and Predict Clinical Outcome in Hepatocellular Carcinoma
    Wenli Li et al, 2021, Disease Markers CrossRef
  33. N6-Methyladenosine RNA Modification in Inflammation: Roles, Mechanisms, and Applications
    Jiahui Luo et al, 2021, Front. Cell Dev. Biol. CrossRef
  34. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment.
    Yingxi Du et al, 2021, Front Pharmacol CrossRef
  35. Expression Status and Prognostic Value of m6A RNA Methylation Regulators in Lung Adenocarcinoma
    Xiuhong Li et al, 2021, Life CrossRef
  36. ATF3 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an N6-Methyladenosine-Based Epitranscriptomic Mechanism
    Xiaochuan Liu et al, 2021, Chem. Res. Toxicol. CrossRef
  37. m6A Modification: A Double-Edged Sword in Tumor Development.
    Runnan Gao et al, 2021, Front Oncol CrossRef
  38. Role of m6A methylation in occurrence and progression of digestive system malignancies
    Rui-Huang Liang et al, 2021, WCJD CrossRef
  39. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
    Lianzi Wang et al, 2021, BMC Cancer CrossRef
  40. m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.
    Congjun Zhang et al, 2021, Front Oncol CrossRef
  41. Characterization of Modification Patterns, Biological Function, Clinical Implication, and Immune Microenvironment Association of m6A Regulators in Pancreatic Cancer
    Kun Fang et al, 2021, Front. Genet. CrossRef
  42. Effect, Mechanism, and Applications of Coding/Non-coding RNA m6A Modification in Tumor Microenvironment
    Chaohua Si et al, 2021, Front. Cell Dev. Biol. CrossRef
  43. Integration Analysis of m6A Related Genes in Skin Cutaneous Melanoma and the Biological Function Research of the SPRR1B
    Shupeng Shi et al, 2021, Front. Oncol. CrossRef
  44. Single-Cell Multiomics Analysis for Drug Discovery
    Sam F. Nassar et al, 2021, Metabolites CrossRef
  45. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
    Yongdong Guo et al, 2021, Front Immunol CrossRef
  46. Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer
    Bowen Huang et al, 2022, Front. Oncol. CrossRef
  47. Comprehensive Analysis of Differentially Expressed Profiles of mRNA N6-Methyladenosine in Colorectal Cancer
    Na Li et al, 2022, Front. Cell Dev. Biol. CrossRef
  48. The N6-Methyladenosine Modification and Its Role in mRNA Metabolism and Gastrointestinal Tract Disease
    Teng Cai et al, 2022, Front. Surg. CrossRef
  49. Interplay Between m6A RNA Methylation and Regulation of Metabolism in Cancer
    Youchaou Mobet et al, 2022, Front. Cell Dev. Biol. CrossRef
  50. Epitranscriptomic Reprogramming Is Required to Prevent Stress and Damage from Acetaminophen
    Sara Evke et al, 2022, Genes CrossRef
  51. An Overview of Epigenetic Methylation in Pancreatic Cancer Progression
    Yuhao Zhao et al, 2022, Front. Oncol. CrossRef
  52. Roles of RNA Modifications in Diverse Cellular Functions
    Emma Wilkinson et al, 2022, Front. Cell Dev. Biol. CrossRef
  53. Methyltransferase-like 3 Aggravates HCC Development via Mediating N6-Methyladenosine of Ubiquitin-Specific Protease 7
    Daiyue Yuan et al, 2022, Journal of Oncology CrossRef
  54. The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma
    Fan Chen et al, 2022, Front. Immunol. CrossRef
  55. Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours
    Zhelin Xia et al, 2022, Front. Pharmacol. CrossRef
  56. Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance
    Sruthi Sritharan et al, 2022, Apoptosis CrossRef
  57. Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.
    Fusheng Zhang et al, 2022, J Hematol Oncol CrossRef
  58. The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer
    Xiaoge Hu et al, 2022, Front. Oncol. CrossRef
  59. Multifaceted Roles of the N6-Methyladenosine RNA Methyltransferase METTL3 in Cancer and Immune Microenvironment
    Chenxi Hu et al, 2022, Biomolecules CrossRef
  60. SETD2 regulates gene transcription patterns and is associated with radiosensitivity in lung adenocarcinoma
    Zihang Zeng et al, 2022, Front. Genet. CrossRef
  61. YTHDF3 Is Involved in the Diapause Process of Bivoltine Bombyx mori Strains by Regulating the Expression of Cyp307a1 and Cyp18a1 Genes in the Ecdysone Synthesis Pathway
    Yanhua Chen et al, 2022, Biomolecules CrossRef
  62. The role of RNA modification in hepatocellular carcinoma
    Qiang Feng et al, 2022, Front. Pharmacol. CrossRef
  63. METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma
    Liting Lu et al, 2022, Front. Cell Dev. Biol. CrossRef
  64. Epigenetic Regulation of Methylation in Determining the Fate of Dental Mesenchymal Stem Cells
    Hui Zhang et al, 2022, Stem Cells International CrossRef
  65. METTL3 suppresses anlotinib sensitivity by regulating m6A modification of FGFR3 in oral squamous cell carcinoma
    Jie Chen et al, 2022, Cancer Cell Int CrossRef
  66. Transcriptome-wide m6A methylome analysis uncovered the changes of m6A modification in oral pre-malignant cells compared with normal oral epithelial cells
    Xun Chen et al, 2022, Front. Oncol. CrossRef
  67. The Role of N6-Methyladenosine Modification in Microvascular Dysfunction
    Ye-Ran Zhang et al, 2022, Cells CrossRef
  68. Identification of genes modified by N6-methyladenosine in patients with colorectal cancer recurrence
    Qianru Zhu et al, 2022, Front. Genet. CrossRef
  69. The Role of m6A Modification and m6A Regulators in Esophageal Cancer
    Yuekao Li et al, 2022, Cancers CrossRef
  70. A dynamic reversible RNA N 6 ‐methyladenosine modification: current status and perspectives
    Zhen Bi et al, 2019, Journal Cellular Physiology CrossRef
  71. N6-methyladenosine RNA methylation: From regulatory mechanisms to potential clinical applications
    Peipei Li et al, 2022, Front. Cell Dev. Biol. CrossRef
  72. RNA Modifications Meet Tumors
    Zhiyuan Yang et al, 2022, CMAR CrossRef